Concert Pharma (CNCE) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharmaceuticals (CNCE) PT Lowered to $18 at UBS
May 6, 2016 9:02 AM EDTUBS analyst Jeffrey Hung lowered his price target on Concert Pharmaceuticals (NASDAQ: CNCE) to $18.00 (from $28.00) but maintained a Buy rating following Q1 results.
Hung commented, "This morning, Concert reported 1Q16 results, but not surprisingly the focus of the call was on the... More
